WHAT IS CLAIMED IS:

1. An antibody that binds to a GARP/TGFβ complex comprising:

a) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 1, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 3; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 4, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 6;

b) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 11, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 14, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 16;

c) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 21, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 22, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 23; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 24, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 26;

d) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 31, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 32, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 33; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 34, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 36;

e) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising

the amino acid sequence set forth in SEQ ID NO: 41, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 44, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 45, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 46;

f) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 51, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 53; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 54, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 56;

g) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 61, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 63; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 64, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 66; or

h) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 105, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 106, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 107; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 108, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 109, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 110.

2. The antibody of claim 1, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 41, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43; and a light chain

variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 44, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 45, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 46.

3. The antibody of claim 1, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 105, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 106, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 107; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 108, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 109, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 110.

4. The antibody of any one of claims 1-3, wherein the antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8;

b) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18;

c) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 28;

d) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 38;

e) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 83;

f) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 48;

g) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84;

h) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 57, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 58;

i) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 67, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 68;

j) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86;

k) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90;

l) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 93, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 94;

m) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 97, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 98;

n) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 101, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 102; or

o) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 111, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 112.

5. The antibody of any one of claims 1-4, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86.

6. The antibody of any one of claims 1-4, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 111, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 112.

7. The antibody of any one of claims 1-6, wherein the antibody comprises a full-length immunoglobulin, a single-chain Fv (scFv) fragment, a Fab fragment, a Fab' fragment, a F(ab')2, a Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a Fv-Fc fusion, a scFv-Fc fusion, a scFv-Fv fusion, a diabody, a tribody, a tetrabody or any combination thereof.

8. The antibody of any one of claims 1-7**,** wherein the antibody comprises a Fc region.

9. The antibody of claim 8, wherein the Fc region comprises a Fc region selected from the group consisting of the Fc regions of IgG1, IgG2, IgG3 and IgG4.

10. The antibody of claim 8 or 9, wherein the Fc region comprises an IgG1 Fc region or an IgG4 Fc region.

11. The antibody of any one of claims 8-10, wherein the Fc region comprises a C-terminal lysine.

12. The antibody of any one of claims 8-10, wherein the Fc region comprises a deletion of a C-terminal lysine.

13. An immunoconjugate comprising the antibody of any one of claims 1-12, linked to a therapeutic agent or a label.

14. The immunoconjugate of claim 13, wherein the therapeutic agent is a cytotoxin or a radioactive isotope.

15. The immunoconjugate of claim 14, wherein the label is selected from the group consisting of a radioisotope, a fluorescent dye and an enzyme.

16. An antigen-recognizing receptor comprising an extracellular antigen-binding domain that comprises an antibody of any one of claims 1-12.

17. The antigen-recognizing receptor of claim 16, which is a Chimeric Antigen Receptor

(CAR).

18. The antigen-recognizing receptor of claim 16 or 17, wherein the antibody is a scFv.

19. An immunoresponsive cell comprising an antigen-recognizing receptor of any one of claims 16-18.

20. The immunoresponsive cell of claim 19, wherein the immunoresponsive cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), a regulatory T cell, a Natural Killer T (NKT) cell and a myeloid cell.

21. The immunoresponsive cell of claim 20, wherein the immunoresponsive cell is a T cell.

22. A pharmaceutical composition comprising a) the antibody of any one of claims 1-12, the immunoconjugate of any one of claims 13-15, or the immunoresponsive cell of any one of claims 19-21, and b) a pharmaceutically acceptable carrier.

23. One or more nucleic acid encoding the antibody of any one of claims 1-12.

24. One or more vector comprising the nucleic acid of claim 23.

25. A host cell comprising the nucleic acid of claim 23 or the vector of claim 24.

26. A method for preparing an antibody of any one of claims 1-12 comprising expressing the antibody in the host cell of claim 25 and isolating the antibody from the host cell.

27. An antibody of any one of claims 1-12 for use as a medicament.

28. An antibody of any one of claims 1-12 for use in treating cancer.

29. A pharmaceutical composition of claim 22 for use as a medicament.

30. A pharmaceutical composition of claim 22 for use in treating cancer.

31. The antibody of claim 28 or the pharmaceutical composition of claim 30, wherein the cancer exhibits high microsatellite instability (MSI).

32. The antibody of claim 28 or the pharmaceutical composition of claim 30, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.

33. A kit comprising an antibody of any one of claims 1-12, an immunoconjugate of any one of claims 13-15, a pharmaceutical composition of claim 22, a nucleic acid of claim 23, a vector of claim 24 or an immunoresponsive cell of claim 19-21.

34. The kit of claim 33, further comprising a written instruction for treating and/or preventing a neoplasm.

35. An anti-GARP/TGFβ antibody and an anti-PD1 antibody for use in treating cancer.

36. The anti-GARP/TGFβ antibody and the anti-PD1 antibody of claim 35, wherein the anti-GARP/TGFβ antibody is an anti-GARP/TGFβ antibody of any one of claims 1-12.

37. The anti-GARP/TGFβ antibody and the anti-PD1 antibody of claim 35 or 36, wherein the cancer exhibits high microsatellite instability (MSI).

38. The anti-GARP/TGFβ antibody and the anti-PD1 antibody of any one of claims 35-37, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.